Considering that PI-IBS is brought on by infection and gut microbiota may be associated with
the onset of symptoms, the modification of altered gut microbiota with nonabsorbable
antibiotics such as rifaximin-α or probiotics is often employed as first-stage treatment.
Research in recent years has also shown the potential benefits of fecal microbiota
transplantation (FMT) for IBS, which is the replacement of a sick recipient's gut microbiota
with fecal material from a healthy donor. Even though the only officially approved indication
for FMT at this time is recurrent Clostridium difficile infection, the effectiveness of FMT
is nevertheless being studied for the treatment of other gastrointestinal and
non-gastrointestinal pathologies including IBS. To date, several controlled and uncontrolled
studies have been conducted to study the effectiveness of FMT for IBS, and most of them have
demonstrated positive results. The investigators have not come across studies devoted to the
study of the effectiveness of FMT in patients with PI-IBS in the available literature. So,
the aim of the current study was to conduct single-centre, randomized clinical trial to
assess the safety, clinical and microbiological efficacy of FMT in patients with PI-IBS.
Phase:
N/A
Details
Lead Sponsor:
Bogomolets National Medical University
Collaborator:
Ukrainian Research and Practical Centre of Endocrine Surgery, Transplantation of Endocrine Organs and Tissues of the Ministry of Health of Ukraine